

Study: ENGOT-ov63/ NIRVANA-1

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery.

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
CN	Cuneo	Ospedale Carle	Marcella Occelli	No
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	No
MB	Monza	Ospedale San Gerardo	Andrea A. Lissoni	No
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	No
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi *	Yes
SO	Sondrio	Ospedale di Sondrio	Alessandro Bertolini	No
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros	No

* **MaNGO Principal Investigator**